Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.49 |
| ▸ | F2 | P00734 | 7/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420102 | 0.82 | F10 (0.50) | F10F2 | |
| SCHEMBL4412919 | 0.80 | F10 (0.65) | F10F2 | |
| SCHEMBL4420358 | 0.78 | F10 (0.47) | F10F2 | |
| SCHEMBL6017015 | 0.75 | F10 (0.57) | F10F2 | |
| SCHEMBL4419547 | 0.73 | F10 (0.71) | F10F2 | |
| SCHEMBL4416555 | 0.72 | F10 (0.57) | F10F2 | |
| SCHEMBL3960916 | 0.71 | F10 (0.56) | F10F2KLK1 | |
| SCHEMBL2780778 | 0.71 | F10 (0.50) | F10F2 | |
| SCHEMBL1456235 | 0.70 | F10 (0.61) | F10F2 | |
| SCHEMBL4414393 | 0.70 | F10 (0.54) | F10F2PLATKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-7365088-B2 | Indazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | disclosed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | F11, F12, F5 | F10 14/4885F2 4/4885PLAT 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.